Role of the p16 tumor suppressor gene in cancer.
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Since its discovery as a CDKI (cyclin-dependent kinase inhibitor) in 1993, the tumor suppressor p16 (INK4A/MTS-1/CDKN2A) has gained widespread importance in cancer. The frequent mutations and deletions of p16 in human cancer cell lines first suggested an important role for p16 in carcinogenesis. This genetic evidence for a causal role was significantly strengthened by the observation that p16 was frequently inactivated in familial melanoma kindreds. Since then, a high frequency of p16 gene alterations were observed in many primary tumors. In human neoplasms, p16 is silenced in at least three ways: homozygous deletion, methylation of the promoter, and point mutation. The first two mechanisms comprise the majority of inactivation events in most primary tumors. Additionally, the loss of p16 may be an early event in cancer progression, because deletion of at least one copy is quite high in some premalignant lesions. p16 is a major target in carcinogenesis, rivaled in frequency only by the p53 tumor-suppressor gene. Its mechanism of action as a CDKI has been elegantly elucidated and involves binding to and inactivating the cyclin D-cyclin-dependent kinase 4 (or 6) complex, and thus renders the retinoblastoma protein inactive. This effect blocks the transcription of important cell-cycle regulatory proteins and results in cell-cycle arrest. Although p16 may be involved in cell senescence, the physiologic role of p16 is still unclear. Future work will focus on studies of the upstream events that lead to p16 expression and its mechanism of regulation, and perhaps lead to better therapeutic strategies that can improve the clinical course of many lethal cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
E2F: a Link Between the Rb Tumor Suppressor Protein and Viral Oncoproteins
Nevins, J. R. (1992) · Science · doi:10.1126/science.1411535 · Cited by 1,506
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
The essentials of DNA methylation
Bird, A. (1992) · Cell · doi:10.1016/0092-8674(92)90526-i · Cited by 948
The retinoblastoma protein binds to a family of E2F transcription factors.
Lees, J. A., Saito, M., Vidal, M., Valentine, M., Look, T., Harlow, E., Dyson, N., & Helin, K. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.12.7813 · Cited by 441
CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki, K., Ono, Y., Henson, J. W., Efird, J. T., von Deimling, A., & Louis, D. N. (1996) · PubMed · Cited by 404
Cell cycle-specific association of E2F with the p130 E1A-binding protein.
Cobrinik, D., Whyte, P., Peeper, D. S., Jacks, T., & Weinberg, R. A. (1993) · Genes & Development · doi:10.1101/gad.7.12a.2392 · Cited by 335
E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo.
Beijersbergen, R. L., Kerkhoven, R. M., Zhu, L., Carlée, L., Voorhoeve, P. M., & Bernards, R. (1994) · Genes & Development · doi:10.1101/gad.8.22.2680 · Cited by 322
p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer
Williamson, M. P., Elder, P. A., Shaw, M. E., Devlin, J., & Knowles, M. A. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.9.1569 · Cited by 179
p16 gene homozygous deletions in acute lymphoblastic leukemia
Quesnel, B., Preudhomme, C., Philippe, N., Vanrumbeke, M., Dervite, I., Lai, J., Bauters, F., Wattel, E., & Fenaux, P. (1995) · Blood · doi:10.1182/blood.v85.3.657.bloodjournal853657 · Cited by 133
Cited by
Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers
Gillison, M. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.709 · Cited by 3,101
Evaluation of the use of therapeutic peptides for cancer treatment
Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 512
BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., De Giorgi, V., Massi, D., Fonsatti, E., Staibano, S., Nappi, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2452 · Cited by 471
p16(MTS-1/CDKN2/INK4a) in Cancer Progression
Rocco, J. W., & Sidransky, D. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5149 · Cited by 470
Self-citationGliomagenesis: genetic alterations and mouse models
Holland, E. C. (2001) · Nature Reviews Genetics · doi:10.1038/35052535 · Cited by 461
Huang, S. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900023 · Cited by 439
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers
Wang, Y., & Deng, B. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10084-4 · Cited by 415
DNA Copy Number Losses in Human Neoplasms
Knuutila, S., Aalto, Y., Autio, K., Björkqvist, A.-M., El-Rifai, W., Hemmer, S., Huhta, T., Kettunen, E., Kiuru-Kuhlefelt, S., Larramendy, M. L., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65166-8 · Cited by 397
Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification
Röwert-Huber, J., Patel, M. J., Forschner, T., Ulrich, C., Eberle, J., Kerl, H., Sterry, W., & Stockfleth, E. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07860.x · Cited by 380
Singal, R., & Ginder, G. D. (1999) · Blood · doi:10.1182/blood.v93.12.4059 · Cited by 365
Pediatric low-grade glioma in the era of molecular diagnostics
Ryall, S., Tabori, U., & Hawkins, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00902-z · Cited by 351
Ahrendt, S. A., Chow, J. T., Xu, L.-H., Yang, S. C., Eisenberger, C. F., Esteller, M., Herman, J. G., Wu, L., Decker, P. A., Jen, J., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.4.332 · Cited by 345
Self-citationCyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation
Sielecki, T. M., Boylan, J. F., Benfield, P. A., & Trainor, G. L. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990256j · Cited by 323
Infante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1248 · Cited by 317
Leary, R. J., Lin, J. C., Cummins, J., Boca, S., Wood, L. D., Parsons, D. W., Jones, S., Sjöblom, T., Park, B.-H., Parsons, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808041105 · Cited by 306
Koch, A., Jeschke, J., Van Criekinge, W., van Engeland, M., & De Meyer, T. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz445 · Cited by 306
Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P., & Knudsen, E. S. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16776 · Cited by 286
Accelerated senescence: An emerging role in tumor cell response to chemotherapy and radiation
Gewirtz, D. A., Holt, S. E., & Elmore, L. W. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.06.024 · Cited by 281
Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation
McDonald, J. I., Celik, H., Rois, L. E., Fishberger, G., Fowler, T., Rees, R., Kramer, A., Martens, A., Edwards, J. R., & Challen, G. A. (2016) · Biology Open · doi:10.1242/bio.019067 · Cited by 275
Emerging therapeutic targets in endometrial cancer
Dedes, K. J., Wetterskog, D., Ashworth, A., Kaye, S. B., & Reis-Filho, J. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.216 · Cited by 270
Toward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252
Nuclear morphology is a deep learning biomarker of cellular senescence
Heckenbach, I., Mkrtchyan, G. V., Ezra, M. B., Bakula, D., Madsen, J. S., Nielsen, M. H., Oró, D., Osborne, B., Covarrubias, A. J., Idda, M. L., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00263-3 · Cited by 232
“In addition, loss of central senescence inducers such as p16 Ink4a is very common in many cancer types 44 .”
BackgroundGenetic and Epigenetic Changes in Human Epithelial Cells Immortalized by Telomerase
Farwell, D. G., Shera, K. A., Koop, J. I., Bonnet, G. A., Matthews, C. P., Reuther, G. W., Coltrera, M. D., McDougall, J. K., & Klingelhutz, A. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65025-0 · Cited by 196
“Loss of p16 expression has been shown to result from deletion, point mutation, and methylation of CpG islands in the promoter.(42) Sequencing analyses of p16 exons 1 and 2 revealed no point mutations or small deletions in the cell lines that had lost p16 expression (data not shown).”
BackgroundDPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma
Biankin, A. V., Morey, A. L., Lee, C.-S., Kench, J. G., Biankin, S. A., Hook, H. C., Head, D. R., Hugh, T. B., Sutherland, R. L., & Henshall, S. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.063 · Cited by 163
Daya-Grosjean, L., & Sarasin, A. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.11.013 · Cited by 142
Hiroyasu, M., Ozeki, M., Kohda, H., Echizenya, M., Tanaka, T., Hiai, H., & Toyokuni, S. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64860-2 · Cited by 61
Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models
Saiki, Y., Jiang, C., Ohmuraya, M., & Furukawa, T. (2021) · Cancers · doi:10.3390/cancers14010071 · Cited by 38
“The other protein of CDKN2A, p14AFR, inhibits MDM-2, a negative regulator of p53, and controls cell cycle progression [86,87].”
BackgroundToyokuni, S., Kong, Y., Cheng, Z., Sato, K., Hayashi, S., Ito, F., Jiang, L., Yanatori, I., Okazaki, Y., & Akatsuka, S. (2020) · Cancers · doi:10.3390/cancers12113320 · Cited by 33
Metadata
- Authors
- Liggett, W. H., & Sidransky, D.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-03
- Volume
- 16
- Issue
- 3
- Pages
- 1197-1206
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2262513754
- Cited by
- 746
- References
- 18
- FWCI
- 16.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.